GSK revises adverse events section on Lexiva label
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has issued a "Dear Doctor" letter in the US to inform physicians that its anti-HIV drug Lexiva (fosamprenavir calcium) may be associated with myocardial infarction and hypercholesterolemia. The company has updated the "adverse reactions" and the "warnings and precautions" sections of the US label to reflect these risks.